IDEXX Laboratories, Inc.
IDXXLast close · Oct 16, 2026560.36+13.18 (+2.41%)
Market cap$44.1B
3 firms' latest targets, last 90 days: median $710.00 ($620.00–$740.00), 27% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-16 | Goldman Sachs | $740.00 | — | +32% |
| 2026-08-11 | Barclays | $710.00 | ▼ 11% | +27% |
| 2026-07-27 | UBS | $620.00 | ▼ 3% | +11% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $3.7B | +9% | $10.06 | +25% | est. $3.6B+0% | est. $9.86 | 7 |
| 2024reported | $3.9B | +6% | $10.67 | +6% | est. $3.9B+0% | est. $10.46 | 8 |
| 2025reported | $4.3B | +10% | $13.08 | +23% | est. $4.3B+0% | est. $12.93 | 9 |
| 2026 | $4.7B | +10% | $14.76 | +14% | $4.7B–$4.7B | $14.71–$14.82 | 11 |
| 2027 | $5.1B | +9% | $16.75 | +14% | $5.1B–$5.2B | $16.34–$17.09 | 11 |
| 2028 | $5.6B | +9% | $19.04 | +14% | $5.5B–$5.7B | $18.42–$19.84 | 11 |
| 2029 | $6.2B | +10% | $22.08 | +16% | $6.1B–$6.2B | $21.85–$22.35 | 5 |
| 2030 | $6.9B | +12% | $25.62 | +16% | $6.9B–$7.0B | $25.35–$25.92 | 5 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.